Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
September 17 - Hedge Funds, News - Comments
The Chinese calendar says 2013 is the year of the snake, but the market says it’s the year of biotech. Major biotechnology ETFs and indices have...
Keep Reading →
September 17 - News - Comments
There are plenty of biotech companies that put all of their eggs in one basket these days. For speculative traders, these stocks can lead to exciting...
Keep Reading →
September 16 - News - Comments
The last several months have been remarkably exciting in the biotech space. For patients, it appears that groundbreaking treatments for hepatitis C and...
Keep Reading →
September 11 - News - Comments
A year ago, Best Buy Co., Inc. (NYSE:BBY) founder Richard Schulze wanted to team up with private equity investors to buy enough shares to take the consumer...
Keep Reading →
August 27 - News - Comments
What’s better than momentum? Mo’ momentum. Let’s take a closer look at five of this past week’s biggest scorchers. Company Aug...
Keep Reading →
August 19 - News - Comments
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)‘s extended phase 3 program for its inhaled insulin,...
Keep Reading →
August 12 - News - Comments
Babe Ruth wasn’t afraid to swing for the fences. That’s how he became Major League Baseball’s home run king for decades. If you’...
Keep Reading →
July 15 - News - Comments
There’s never a shortage of losers in the stock market. Let’s take a closer look at five of this past week’s biggest sinkers. Company...
Keep Reading →
July 15 - News - Comments
For the last few weeks, there has been a heated debate regarding the success or lack thereof from biotechnology company Amarin Corporation plc (ADR) (...
Keep Reading →
July 10 - News - Comments
“More means less.” Amarin Corporation plc (ADR) (NASDAQ:AMRN) demonstrated this seemingly contradictory maxim today following its announcement...
Keep Reading →
July 9 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
July 5 - Hedge Funds - Comments
While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with...
Keep Reading →
July 1 - News - Comments
Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices. While...
Keep Reading →
June 27 - News - Comments
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors. The biotech’s fish oil, Vascepa, will get its day in front of a Food and...
Keep Reading →
June 20 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
June 20 - Hedge Funds - Comments
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has recently launched its primary product candidate Vascepa into the market. The drug is an omega-3 fatty acid...
Keep Reading →
June 10 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN) announced the acquisition of Omthera Pharmaceuticals Inc (NASDAQ:OMTH), a company that went public just last month (April...
Keep Reading →
June 10 - News - Comments
GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s diabetes drug Avandia causes heart issues. Or maybe it doesn’t. Either way, regulators figured the...
Keep Reading →
June 10 - News - Comments
Regardless of Anchor, Things Are Looking Up! It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors. The...
Keep Reading →
June 3 - News - Comments
The biotechnology sector is rapidly evolving, and what was a near-guarantee of success of getting a drug approved by the Food and Drug Administration...
Keep Reading →
June 3 - News - Comments
We’ve been speculating for almost a year that Amarin Corporation plc (ADR) (NASDAQ:AMRN) would be purchased by AstraZeneca plc (ADR) (NYSE:AZN...
Keep Reading →
May 29 - News - Comments
Merck & Co., Inc. (NYSE:MRK) just can’t get enough of its stock. And the pharma wants it now. The company announced Tuesday after the close...
Keep Reading →
May 24 - News - Comments
A study published in The New England Journal of Medicine testing omega-3 fatty acids — commonly found in fish oil — in patients with risk...
Keep Reading →
May 13 - News - Comments
It’s not just about offering a better drug, but it’s also about launching it at the right time in the market. This is what I learned while studying...
Keep Reading →
April 28 - News - Comments
As an investor, it pays to follow the cash. If you figure out how a company moves its money, you might eventually find some of that cash flowing into...
Keep Reading →
March 27 - News - Comments
Some stocks take a pounding, but there’s usually what they call a dead-cat bounce. Even if a stock’s inevitable path is to head lower, there...
Keep Reading →
March 25 - News - Comments
Sequester or no sequester, the folks at the Food and Drug Administration look to be quite busy in 2013. Their schedules are full with plenty of important...
Keep Reading →
March 25 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
March 20 - Hedge Funds - Comments
Last year, a number of drugs received FDA approval. The drug authority has rolled out one approval after another, maybe to compensate for the patent cliff...
Keep Reading →
March 14 - News - Comments
It’s not just Catholics watching a certain Vatican City smokestack. As cardinals gather to elect a new pope, the conclave uses a smokestack to communicate...
Keep Reading →
March 14 - News - Comments
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech...
Keep Reading →
March 6 - News - Comments
The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including...
Keep Reading →
February 26 - News - Comments
All throughout Wall Street we keep hearing about Amarin Corporation plc (ADR) (NASDAQ:AMRN) being bought out by some type of Big Pharma company in the...
Keep Reading →
February 22 - News - Comments
Baltimore won. Beyonce rocked. But some health-care stocks didn’t have such great experiences. Here are three of the most horrendous performers...
Keep Reading →
February 9 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
February 6 - Hedge Funds - Comments
After several days of focusing on the economy, investors have had their attention pulled squarely back on earnings season, and some of the news hasn&#...
Keep Reading →
January 21 - News - Comments
